206 related articles for article (PubMed ID: 26910909)
1. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
[TBL] [Abstract][Full Text] [Related]
2. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
Claessens YE; Bouscary D; Dupont JM; Picard F; Melle J; Gisselbrecht S; Lacombe C; Dreyfus F; Mayeux P; Fontenay-Roupie M
Blood; 2002 Mar; 99(5):1594-601. PubMed ID: 11861273
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
5. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD.
Claessens YE; Park S; Dubart-Kupperschmitt A; Mariot V; Garrido C; Chrétien S; Dreyfus F; Lacombe C; Mayeux P; Fontenay M
Blood; 2005 May; 105(10):4035-42. PubMed ID: 15677568
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
7. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction.
Fontenay-Roupie M; Bouscary D; Guesnu M; Picard F; Melle J; Lacombe C; Gisselbrecht S; Mayeux P; Dreyfus F
Br J Haematol; 1999 Aug; 106(2):464-73. PubMed ID: 10460607
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.
Tuettenberg J; Seiz M; Debatin KM; Hollburg W; von Staden M; Thiemann M; Hareng B; Fricke H; Kunz C
Int Immunopharmacol; 2012 May; 13(1):93-100. PubMed ID: 22446296
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice.
Otsuki T; Nagakura S; Wang J; Bloom M; Grompe M; Liu JM
J Cell Physiol; 1999 Apr; 179(1):79-86. PubMed ID: 10082135
[TBL] [Abstract][Full Text] [Related]
11. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
Raimbault A; Itzykson R; Willems L; Rousseau A; Chapuis N; Mathis S; Clauser S; Radford-Weiss I; Bouscary D; Fontenay M; Kosmider O; Bardet V
Cytometry B Clin Cytom; 2019 May; 96(3):215-222. PubMed ID: 30963682
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric analysis of the expression of Fas/Fasl in bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression.
Ribeiro E; Lima CS; Metze K; Lorand-Metze I
Leuk Lymphoma; 2004 Feb; 45(2):309-13. PubMed ID: 15101716
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.
Tehranchi R; Fadeel B; Forsblom AM; Christensson B; Samuelsson J; Zhivotovsky B; Hellstrom-Lindberg E
Blood; 2003 Feb; 101(3):1080-6. PubMed ID: 12393561
[TBL] [Abstract][Full Text] [Related]
15. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract][Full Text] [Related]
16. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of in vitro characteristics of colony-forming cells in myelodysplastic syndrome and comparison with that in non-severe aplastic anemia].
Zhang TJ; Feng M; Zheng YZ; Li XX; Xu ZF; Qin TJ; Zhang Y; Yang YB; Liu JX; Ren YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):516-21. PubMed ID: 22967409
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 and CD35 during normal and myelodysplastic erythropoiesis.
Laranjeira P; Rodrigues R; Carvalheiro T; Constanço C; Vitória H; Matarraz S; Trindade H; Órfão A; Paiva A
Leuk Res; 2015 Mar; 39(3):361-70. PubMed ID: 25582385
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.
Backx B; Broeders L; Hoefsloot LH; Wognum B; Löwenberg B
Leukemia; 1996 Mar; 10(3):466-72. PubMed ID: 8642863
[TBL] [Abstract][Full Text] [Related]
20. Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.
Maki K; Sasaki K; Nagata Y; Nagasawa F; Nakamura Y; Ogawa S; Mitani K
Int J Hematol; 2014 Oct; 100(4):361-9. PubMed ID: 25056847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
